# SUPPLEMENTARY MATERIAL

**Table S1** Sensitivity analyses on changes in eGFR and urine protein-to-creatinine ratio

|  |  |  |
| --- | --- | --- |
| **Changes in eGFR, restricted to individuals who had TDF replaced by TAF without further changes in ART** | | |
|  | **Year before TAF** | **Year after TAF** |
| eGFR 60 – 89 mL/min/1.73m2 (n = 45) | -2.1 mL/min/1.73m2  (95% CI -4.1 to -0.1) | 4.2 mL/min/1.73m2  (95% CI 1.5 to 6.9) |
| eGFR below 60 mL/min/1.73m2 (n = 13) | -2.6 mL/min/1.73m2  (95% CI -6.2 to 1.0) | 9.1 mL/min/1.73m2  (95% CI 3.9 to 14.3) |

|  |  |
| --- | --- |
| **Changes in urine protein-to-creatinine ratio, restricted to individuals who had TDF replaced by TAF without further changes in ART (n = 54)** | |
| **Year before TAF** | **Year after TAF** |
| -0.2 mg/mmol (95% CI -4.8 to 4.3) | -6.8 mg/mmol (95% CI -11.9 to -1.9) |
| **eGFR** estimated glomerular filtration rate, **TDF** tenofovir disoproxil fumarate, **TAF** tenofovir alafenamide, **ART** antiretroviral therapy | |

**Table S2** Sensitivity analyses on changes in ALT levels

|  |  |  |
| --- | --- | --- |
| **Restricted to individuals who had TDF replaced by TAF without further changes in ART** | | |
|  | **Year before TAF** | **Year after TAF** |
| ALT normal (n = 40) | -0.9 IU/L (-4.8 to 3.0) | 0.6 IU/L (-5.0 to 6.2) |
| ALT elevated (n = 22) | 6.6 IU/L (0.8 to 12.3) | -16.0 IU/L (-23.6 to -8.4) |
|  |  |  |
| **Restricted to individuals without EFV in their ART regimen** | | |
|  | **Year before TAF** | **Year after TAF** |
| ALT normal (n = 64) | -1.2 IU/L (-3.6 to 1.3) | 0.2 IU/L (-3.3 to 3.75) |
| ALT elevated (n = 29) | 6.8 IU/L (2.8 to 10.9) | -14.3 IU/L (-19.8 to -8.8) |
| **ALT** Alanine aminotransferase, **TDF** tenofovir disoproxil fumarate, **TAF** tenofovir alafenamide, **ART** antiretroviral therapy, **EFV** Efavirenz. | | | |